HK1252811A1 - 用於去勢治療相關症狀之治療的化合物 - Google Patents

用於去勢治療相關症狀之治療的化合物

Info

Publication number
HK1252811A1
HK1252811A1 HK18112116.4A HK18112116A HK1252811A1 HK 1252811 A1 HK1252811 A1 HK 1252811A1 HK 18112116 A HK18112116 A HK 18112116A HK 1252811 A1 HK1252811 A1 HK 1252811A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treatment
associated symptoms
androgen deprivation
deprivation therapy
Prior art date
Application number
HK18112116.4A
Other languages
English (en)
Inventor
Charles Thomas Benson
Hannah Yu
Rachel Nicole Richey
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1252811A1 publication Critical patent/HK1252811A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
HK18112116.4A 2014-09-11 2017-07-20 用於去勢治療相關症狀之治療的化合物 HK1252811A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11

Publications (1)

Publication Number Publication Date
HK1252811A1 true HK1252811A1 (zh) 2019-06-06

Family

ID=54151401

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112116.4A HK1252811A1 (zh) 2014-09-11 2017-07-20 用於去勢治療相關症狀之治療的化合物

Country Status (23)

Country Link
US (4) US10758515B2 (zh)
EP (2) EP3191094B1 (zh)
JP (4) JP6893171B2 (zh)
KR (5) KR20190015628A (zh)
CN (4) CN106794178A (zh)
AP (1) AP2017009795A0 (zh)
AU (2) AU2015315431C1 (zh)
BR (2) BR122018007412B1 (zh)
CA (2) CA2956514C (zh)
EA (2) EA033606B1 (zh)
ES (1) ES2779978T3 (zh)
HK (1) HK1252811A1 (zh)
IL (3) IL279209B2 (zh)
JO (2) JOP20180072A1 (zh)
MA (1) MA45416A (zh)
MX (2) MX2017003140A (zh)
MY (2) MY198753A (zh)
NZ (1) NZ728612A (zh)
SG (2) SG10201809673RA (zh)
TW (1) TWI616201B (zh)
UA (1) UA120099C2 (zh)
WO (1) WO2016040234A1 (zh)
ZA (1) ZA201802680B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1592658B1 (en) * 2003-01-13 2013-04-24 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
TW200817331A (en) 2006-05-31 2008-04-16 Glaxo Group Ltd Novel heterocyclic compounds
BRPI0713198A2 (pt) * 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
PL2222636T3 (pl) 2007-12-21 2014-04-30 Ligand Pharm Inc Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
WO2014069510A1 (ja) * 2012-10-31 2014-05-08 富山化学工業株式会社 新規アミン誘導体またはその塩
CN105814052B (zh) * 2013-12-09 2018-01-12 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
IL279209B2 (en) 2023-02-01
US20200390744A1 (en) 2020-12-17
JO3609B1 (ar) 2020-08-27
KR20170040338A (ko) 2017-04-12
EP3191094B1 (en) 2020-02-19
BR112017002449A2 (pt) 2017-12-05
US20170172992A1 (en) 2017-06-22
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
UA120099C2 (uk) 2019-10-10
AU2015315431C1 (en) 2018-08-02
CA3067289A1 (en) 2016-03-17
JOP20180072A1 (ar) 2019-01-30
AU2018202714B2 (en) 2019-06-20
US20190111039A1 (en) 2019-04-18
SG10201809673RA (en) 2018-12-28
EA201790220A1 (ru) 2017-07-31
IL250291A0 (en) 2017-03-30
CN108440497A (zh) 2018-08-24
AU2018202714A1 (en) 2018-05-17
NZ728612A (en) 2018-03-23
MY195767A (en) 2023-02-10
KR20180041268A (ko) 2018-04-23
KR20220132669A (ko) 2022-09-30
CN113521068A (zh) 2021-10-22
EP3375444A1 (en) 2018-09-19
IL279209B (en) 2022-10-01
SG11201701630VA (en) 2017-03-30
CA3067289C (en) 2023-04-04
US10758515B2 (en) 2020-09-01
EP3191094A1 (en) 2017-07-19
JP2023145479A (ja) 2023-10-11
IL250291B (en) 2020-09-30
EA033606B1 (ru) 2019-11-08
JP2019089795A (ja) 2019-06-13
TWI616201B (zh) 2018-03-01
EA201891008A2 (ru) 2018-09-28
EA034553B1 (ru) 2020-02-19
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
AU2015315431A1 (en) 2017-03-09
JP2017527584A (ja) 2017-09-21
JP2022000432A (ja) 2022-01-04
JP6938550B2 (ja) 2021-09-22
KR102619415B1 (ko) 2024-01-02
TW201618782A (zh) 2016-06-01
JP6893171B2 (ja) 2021-06-23
MX2017003140A (es) 2017-05-23
IL258651B (en) 2021-02-28
AU2015315431B2 (en) 2018-03-08
JP7349480B2 (ja) 2023-09-22
CA2956514A1 (en) 2016-03-17
BR122018007412B1 (pt) 2022-08-23
WO2016040234A1 (en) 2016-03-17
US10799478B2 (en) 2020-10-13
ES2779978T3 (es) 2020-08-21
KR20190015628A (ko) 2019-02-13
ZA201802680B (en) 2020-08-26
IL258651A (en) 2018-06-28
EA201891008A3 (ru) 2019-03-29
CA2956514C (en) 2023-04-18
MA45416A (fr) 2019-04-24
KR20210083370A (ko) 2021-07-06
US20240148694A1 (en) 2024-05-09
MX2021014120A (es) 2022-01-04
MY198753A (en) 2023-09-23
AP2017009795A0 (en) 2017-03-31
KR102024493B1 (ko) 2019-09-23

Similar Documents

Publication Publication Date Title
IL250960B (en) Combined treatment of sinecriviroc for the treatment of leprosy
IL249065A0 (en) Combination of treatments for cancer treatment
IL276733A (en) Use of Aribolin in cancer treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL251904A0 (en) Epilimod for use in the treatment of melanoma
IL247969B (en) A medicinal component for use in the treatment of infections
IL279209A (en) Treatment of symptoms associated with androgen deprivation therapies
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL246855A0 (en) Materials for use in the treatment of retinitis
IL252493B (en) Compounds for use in the prevention or treatment of cancer
ZA201408464B (en) Composition for the use in treatment of asthma